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ascertained.Methods Seventy-three SQTS patients (84% male; age, 26  15 years; corrected QT interval, 329  22 ms) were studied, and
62 were followed for 60  41 months (median, 56 months).Results Cardiac arrest (CA) was the most frequent presenting symptom (40% of probands; range, <1 month to 41 years).
The rate of CA was 4% in the ﬁrst year of life and 1.3% per year between 20 and 40 years; the probability of a ﬁrst
occurrence of CA by 40 years of age was 41%. Despite the male predominance, female patients had a risk proﬁle
superimposable to that of men (p ¼ 0.49). The yield of genetic screening was low (14%), despite familial disease
being present in 44% of kindreds. A history of CA was the only predictor of recurrences at follow-up (p< 0.0000001).
Two patterns of onset of ventricular ﬁbrillation were observed and were reproducible in patients with multiple
occurrences of CA. Arrhythmias occurred mainly at rest.Conclusions SQTS is highly lethal; CA is often the ﬁrst manifestation of the disease with a peak incidence in the ﬁrst year of life.
Survivors of CAhavea highCA recurrence rate; therefore, implantation of a deﬁbrillator is strongly recommended in this
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13; revised manuscript received September 8,To date, approximately 100 SQTS patients have been
reported in the published data, and the largest review
collected 61 subjects (5–7); due to the small number of cases
identiﬁed, the natural history of the disease is incompletely
understood, and uncertainties exist about all aspects of
SQTS, from diagnosis to risk stratiﬁcation and management.
See page 1309
Diagnostic criteria for SQTS are debated and the cutoff
value of the QT interval to suspect/diagnose the disease is
not established: there is a gray area for the corrected QT
(QTc) interval between 370 and 330 ms, for which different
authors have selected their preferred limit (6). A diagnostic
score for SQTS has been proposed (6), and recently a modi-
ﬁed version has been reported, suggesting that this may also
provide prognostic indications (7). Neither criterion, how-
ever, has been validated in independent populations, and
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1301their efﬁcacy in identifying the subjects at risk of life-
threatening events remains unproven.
Because registries are a valuable approach to advance
medical knowledge of rare diseases, in 2003, we added to
our inherited arrhythmias database a section for collecting
SQTS cases. Here we present for the ﬁrst time data per-
taining to 73 SQTS patients identiﬁed in 47 families.ECG = electrocardiogram
ICD = implantable
cardioverter-deﬁbrillator
IQR = interquartile range
PES = programmed
electrical stimulation
QTc = corrected QT
SQTS = short QT syndrome
VEB = ventricular ectopic
beat
VF = ventricular ﬁbrillation
VT = ventricular tachycardiaMethods
Deﬁnitions. SQTS was deﬁned as a QTc interval 340 ms
or QTc interval between 341 ms and 360 ms and 1 or more
of the following: history of CA or syncope, a family history
of unexplained CA at a young age (40 years of age or
younger), or a family history of SQTS. Syncope was deﬁned
as a transient loss of consciousness in the absence of alter-
native explanations (e.g., labyrinthitis, orthostatic hypoten-
sion, or clearly vagally mediated events). Arrhythmic storm
(ArrS) was deﬁned as 2 separate episodes of ventricular
ﬁbrillation/ventricular tachycardia (VF/VT) within 24 h
requiring resuscitation/deﬁbrillation.
Study population and clinical evaluation. Of the 63
patients referred to us as “suspected SQTS” on the basis of
the presence of a QTc interval 360 ms, 47 satisﬁed
criteria for enrollment in this study. Four were victims of
sudden death with a negative autopsy and an electrocar-
diogram (ECG) conﬁrming the presence of a short QT
interval. Cascade screening of family members identiﬁed 26
clinically affected relatives. Additionally, 18 young victims
of sudden death without an ECG were identiﬁed in the
47 families, but they were not included in the main study
given the uncertainty about the cause of death. However,
because excluding these victims of sudden death may
underestimate the severity of the disease, we present the
analysis of the natural history of our cohort both including
and excluding these patients.
In all patients, a 12-lead ECG was obtained at a stable
heart rate close to 60 beats/min during daylight hours to
limit the confounding effect of diurnal variability of the QT
interval (8). The following electrocardiographic parameters
(paper speed of 25 mm/s and 200% magniﬁcation) were
measured: PR interval, RR interval, QT interval/QTc in-
terval, QRS interval, and J point to T wave peak (J-Tpeak)
interval. The QT interval was measured using the tangent
method in the precordial lead presenting the highest T-wave
amplitude (either V2 or V3 in 74% of cases) (8). The QTc
interval was calculated using Bazett’s formula.
We calculated the modiﬁed SQTS score (7) for 34 pro-
bands for whom all the parameters needed were available.
To limit potential bias, we repeated the analysis for all 40
probands with follow-up, allocating maximal scores for
missing information.
Genetic screening. DNA sequencing of the open reading
frame of the KCNH2, KCNQ1, and KCNJ2 genes was
performed in 42 probands and in 3 affected relatives of 3
deceased probands. Screening of CACNA1C and CACNB2genes was performed after the
link between mutations in the 2
genes was reported in the pub-
lished data (9). At that time,
DNA suitable for genotyping
was available for 35 of the
45 previously-mentioned subjects.
Genetic analysis was per-
formed in the laboratory of the
Maugeri Foundation; 1 sample
was genotyped by Familion,
PGxHealth, Transgenomic, Inc.
(Omaha, Nebraska).
The allelic frequency in the
general population of the variants
identiﬁed was determined using
the Exome Variant Server data-
base (10): a minor allele frequency
0.04 was used as a cutoff to
distinguish mutations from vari-
ants of unknown signiﬁcance (11). CACNA2D1 was not
screened because the only variant reported has a minor allele
frequency of 0.1% in Caucasians (12); we do not consider this
a pathogenic DNA change, according to our genetic coun-
seling rules.
For novel mutations or mutations with uncertain func-
tional signiﬁcance, we performed in vitro characterization
using patch clamp techniques.
Follow-up. Our study population included 47 probands
and their 26 family members, totaling 73 SQTS patients.
Four were victims of sudden death, and 7 were lost at
follow-up; the remaining 62 patients were followed for 60 
41 months (median, 56 months; interquartile range, 43
months).
Statistical analysis. Data are expressed as percent, mean 
SD, or median with interquartile range (IQR). Univariate
analyses used the chi-square or Fisher exact test for cate-
gorical data, and the t test or 1-way analysis of variance for
continuous variables; for skewed distributions (follow-up
durations), a Mann-Whitney test was used. CA-free survival
was determined applying Kaplan-Meier analysis; log-rank
tests were used for signiﬁcance. Signiﬁcance was deﬁned
as p < 0.05.
Results
Demographic and clinical proﬁles of the study population.
Demographic and electrocardiographic characteristics of
the study population are shown in Table 1. The reasons for
referral of the 47 probands included CA (n ¼ 19), syncope
(n ¼ 9), family history of CA (n ¼ 2), or the incidental
ﬁnding of a short QTc interval (n ¼ 17). Twelve probands
(26%) had a family history of sudden death in young
subjects; 4 had multiple sudden death victims (2.5  0.6) in
their family.
Cascade screening was accepted by 36 of 47 families: 1
or more affected relatives were identiﬁed in 16 families






(N ¼ 73) p Value*
Male 42 (89) 19 (73) 61 (84) 0.101
Age at enrollment, yrs 23  11 33  19 26  15 0.015
RR interval, ms 941  125 935  94 939  115 0.853
QT interval, ms 317  31 321  29 319  30 0.626
QTc interval, ms 328  23 332  20 329  22 0.481
Values are n (%) or mean  SD. *p values are for comparisons between probands and affected relatives.
QTc ¼ corrected QT (interval).
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1302(44%). Overall, 26 of 54 screened relatives (48%) satisﬁed
our inclusion criteria.
Thirty-nine of 73 patients (53%) had symptoms prompt-
ing medical attention: CA (n ¼ 19), syncope (n ¼ 11), pal-
pitations (n ¼ 7), and atypical chest pain (n ¼ 2).
No differences in age, sex, or electrocardiographic pa-
rameters were found among patients with different clinical
manifestations (Fig. 1, Table 2).
We observed that 20 of 73 patients (27%) experienced
at least 1 occurrence of CA, 15% of which occurred with-
in the ﬁrst year of life. The cumulative probability of
experiencing a ﬁrst occurrence of CA by 40 years of age
was 41%. We also analyzed the enlarged population, in-
cluding the 18 young victims of sudden death without an
ECG identiﬁed in the families; here, 38 of 91 patients
(42%) experienced CA, increasing the cumulative proba-
bility of the occurrence of CA to 54%. Overall, the prob-
ability of experiencing CA in SQTS between birth and
40 years of age is estimated at between 40% and 50%
(Fig. 2).Figure 1
Patients Grouped According to QTc Interval and
the Most Severe Symptom Experienced
Each bar represents the number of patients with QTc values falling into each
10-ms interval (lower number inclusive). There was no signiﬁcant correlation
between QTc interval and symptoms (n ¼ 73, p ¼ 0.35). QTc ¼ corrected QT.Genetic screening. A pathogenic mutation in potassium
channels was identiﬁed in 5 of 45 patients (11%): 2 (4.4%)
in the KCNJ2 gene (D172N, E299V), 2 (4.4%) in KCNH2
(N588K, T618I), and 1 (2.2%) in KCNQ1 (R259H).
One patient (1/35, 2.9%) carried a CACNA1C mutation
(R1977Q) (Fig. 3). The R259H and R1977Q variants
were identiﬁed for the ﬁrst time in SQTS patients, and
their functional effect was conﬁrmed by in vitro character-
ization (data not shown). All other mutations had been
previously studied (13,14).
Segregation studies found that 3 mutations were inheri-
ted, whereas 2, being absent in both parents, were consid-
ered likely de novo. The last genotype-positive patient had
been adopted, and no information was available on her
biological parents.
Interestingly, the penetrance of mutations, deﬁned by
a QTc interval 360 ms, was 100% in the pedigrees
with multiple carriers (n ¼ 3 probands and n ¼ 4 family
members).
Electrocardiographic data from 61 patients with complete
genetic screening showed signiﬁcantly shorter QTc inter-
vals in mutation carriers versus noncarriers (p ¼ 0.002)
(Table 3). However, no difference was observed in the
occurrence of CA in SQTS patients with a likely pathogenic
mutation and those without (p ¼ 0.496) (Online Fig. 1).
Follow-up. At follow-up, an implantable cardioverter-
deﬁbrillator (ICD) was implanted in 16 of 62 patients
(single-chamber in 12 and dual-chamber in 4): 11 patients
received an ICD after surviving CA, 3 because of a family
history of CA and 2 because of an extremely short QTc
interval (<300ms). Four CA survivors did not receive an ICD:
1had irreversible anoxic brain injury and3 refused implantation.Table 2
Comparison of Demographic and Electrocardiographic
Parameters on the Basis of Clinical Manifestations






(n ¼ 20) p Value*
Male 32 (78) 11 (92) 18 (90) 0.353
Age at event, yrs d 21  11 25  13 0.453
RR interval, ms 948  93 938  153 920  132 0.682
QT interval, ms 321  30 314  29 317  32 0.765
QTc interval, ms 330  22 326  24 331  22 0.802
Values are mean  SD or n (%). *p values are for comparisons of all 3 groups together.
CA ¼ cardiac arrest; QTc ¼ corrected QT (interval).
Figure 2 Cardiac Arrest-Free Survival
Kaplan-Meier analysis: blue line represents main study cohort (n ¼ 73); green line
represents main study cohort plus the 18 young victims of sudden death without
an electrocardiogram (ECG) (N ¼ 91). pts ¼ patients.
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1303During 60  41 months of follow-up (median, 56 [IQR:
36 to 79] months), 10 of 62 patients (16%) experienced at
least 1 occurrence of CA (3.2% per year) (Online Fig. 2).
Nine of them had already survived an occurrence of CA: 7
had an ICD and were appropriately shocked, 1 was resus-
citated by an external deﬁbrillator, and 1 who had refused an
ICD died.
The annual CA rate at follow-up was 10.6% among
patients who had already experienced CA and 0.4% in those
without a history of CA before the diagnosis (Fig. 4). The
median follow-up in the 2 groups was not signiﬁcantly
different (median, 65 [IQR: 47 to 99] months vs. 53 [IQR:
21 to 76] months; p ¼ 0.106).
ICD-related complications occurred in 5 of 16 patients
and included a shock during atrial ﬁbrillation with a rapid
ventricular response (n ¼ 1), a shock for sinus tachycardia
(n ¼ 1), infection requiring device extraction (n ¼ 2), and
psychological distress (n ¼ 1).
Triggers and risk factors for CA. Twenty patients expe-
rienced CA, of whom 10 had multiple events. A total of
33 separate occurrences of CA were counted: 25 occurred
during rest, sleep, or quiet routine activities (20 at rest/
during sleep, 3 while eating, and 2 while driving); 3 during
emotional stress; and 2 during effort. The remaining 3
occurrences of CA were in infants under uncertain cir-
cumstances. Nine of 20 patients (45%) who experienced
CA had an ArrS, and 3 had an ArrS recurrence during
follow-up. Six of 9 patients had 3 VF/VT episodes per
storm.
Patient-speciﬁc triggers for CA were found in 7 patients
with recurrent episodes; CA occurred reproducibly under
resting conditions or during sleep in 5 patients, in 1 patient
while eating; and in 1 patient during emotional stress.Univariate analysis was used to identify predictors of CA.
Assessed parameters included sex, QT and QTc intervals,
history of syncope, familial versus sporadic disease, family
history of CA,mutation-positive status, arrhythmia induction
with programmed electrical stimulation (PES), and a history
of resuscitated CA. Only the last parameter was associated
with an increased risk of CA.
Patients resuscitated from a previous CA had a signi-
ﬁcantly greater rate of recurrence of life-threatening
arrhythmias during follow-up (9 of 14 patients) compared
with patients who had never experienced CA (1 of 48
patients; log-rank test, p < 0.0000001; hazard ratio: 37.5;
95% conﬁdence interval: 4.7 to 297.7; p ¼ 0.01) (Fig. 4).
PES was performed in 20 patients with follow-up: VF
was induced in 4 of 20 patients, and only 1 (25%) of them
experienced CA, whereas 6 of 16 (38%) noninducible
patients experienced CA (p ¼ 1.0; no difference in follow-
up duration, p ¼ 0.38).
We assessed the performance of the recently proposed
prognostic SQTS score (7) in 34 probands for whom we
had complete information: 21 patients had a score of 3,
corresponding to a “good prognosis.” The remaining 13
patients had a score of 4, indicating an adverse prognosis.
Over a median follow-up of 56 (IQR: 32 to 83) months, 8
patients experienced CA, 5 of them had a score of 3. The
incidence of CA was 4.6% per year in the good prognosis
group and 4.2% per year in the adverse prognosis group
(p ¼ 0.888) during a median follow-up of 55 (IQR: 31 to
77) months versus 58 (IQR: 25 to 113) months (p ¼ 0.889)
(Online Fig. 3). When patients with incomplete scoring data
were also considered, the incidence of CA remained similar
(5.3% and 4.2% per year in the good and bad prognosis
groups; p ¼ 0.734) during a median follow-up of 55
(IQR: 19 to 76) months versus 67 (IQR: 31 to 96) months
(p ¼ 0.443).
Extrasystolic beats initiating VF/VT. We documented
VF onset in 5 patients with an ICD (Fig. 5A). In 3 patients,
the ﬁrst beat of VF had a short coupling interval (CI)
(basal QTc interval, 337  14 ms; CI, 237  12 ms; range,
230 to 250 ms), whereas the other 2 exhibited a long CI
(basal QTc interval, 334  6 ms; CI, 340 ms and 350 ms).
No short-long-short onset sequences were observed.
In all patients, we found that isolated ventricular ectopic
beats (VEBs) and/or the initiating beat of polymorphic
nonsustained VT had the same CI of the beat precipitating
VF (Fig. 5). Arrhythmias triggered by a short-coupled VEB
presented the morphology of torsade de pointes and subse-
quently degenerated into VF. Arrhythmic events triggered
by a long-coupled VEB exhibited disorganized electrical
activity from the ﬁrst beat.
In 2 patients with multiple documented episodes of VF,
the CI of the initiating beat was identical in all episodes in
the same subject (Figs. 6A and 6B). In 1 patient, VF
recurred during amiodarone infusion, precipitated by a
different, longer coupled extrasystole (CI, 320 ms vs. 230 ms)
(Fig. 6A).
Figure 3 Characteristics of Genotype-Positive Families
Each row refers to a kindred. Columns from left to right show gene and mutation identiﬁed; ECG of probands; the family tree; QTc interval duration; symptoms at enrollment, and
events at follow-up for each mutation carrier, as numbered in the family tree. In the pedigree column, affected subjects are indicated by the solid symbols, unaffected subjects by
open symbols, and sudden death victims by the grey symbols. þ ¼ mutation carrier;  ¼ mutation noncarrier;/ ¼ probands; ☐ ¼ male patients; ¼ female patients. The
asterisk indicates a novel mutation. AF ¼ atrial ﬁbrillation; CA ¼ cardiac arrest; ECG ¼ electrocardiogram; ICD ¼ implantable cardioverter-deﬁbrillator; NSVT ¼ nonsustained
ventricular tachycardia; QTc ¼ corrected QT interval.
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1304Discussion
In the present study, we report data from a cohort of 73
SQTS patients followed over a mean period of 5 years. The
analysis of our population provides novel insights into the
natural history, genetic proﬁle, risk stratiﬁcation schemes,
and arrhythmogenesis of SQTS.
Natural history of patients with SQTS. The paucity of
SQTS patients reported in the published data is consistent
with the nature of the genetic defects: gain-of-functionTable 3
Comparison of Demographic and Electrocardiographic






(n ¼ 51) p Value
Male 5 (50) 46 (91) 0.007
Age at enrollment, yrs 21  15 27  16 0.287
PR interval, ms 151  23 144  22 0.378
RR interval, ms 866  146 943  106 0.143
QT, ms 279  41 325  24 0.006
QTc, ms 300  26 335  17 0.002
QRS, ms 80  12 82  11 0.639
J-T peak, ms 128  46 170  27 0.029
Values are n (%) or mean  SD.
J-Tpeak ¼ J point to T wave peak; QTc ¼ corrected QT (interval).mutations in proteins encoding voltage-dependent ion
channels are limited by the fact that most amino acid
changes are deleterious for these careful evolutionary-crafted
structures. We should therefore anticipate that the man-
agement of SQTS patients will remain on the basis of small
observational studies for quite some time.
Until now, the natural history of SQTS has been
described by 1 multicenter study of 29 subjects (15).
Our single-center cohort has twice the number of patients
and allows a better deﬁnition of the age-related risk of
death in SQTS. We calculated that in the 2006 study by
Giustetto et al. (15), the annual rate of a ﬁrst CA was 1.1%
(10 of 29 patients had a ﬁrst CA over a mean observation
period of 32 years); likewise in our study group the annual
rate of a ﬁrst CA was 0.9% (20 of 73 patients had a ﬁrst
CA during a mean observation period of 31 years). Our
data identify an interesting distribution of the occurrence
of a ﬁrst CA over time. We observed a peak incidence of
CA in the ﬁrst year of life (4% per year). Beyond these
early months, we observed a quiescent phase encompassing
adolescence, followed by an annual CA event rate of 1.3%
between 20 and 40 years of age. Because SQTS and Brugada
syndrome (BrS) belong to the spectrum of early repolariza-
tion syndromes (16), it is interesting to compare their nat-
ural histories.
Figure 4
CA-Free Survival at Follow-up by CA Occurrence
Before Enrollment
Kaplan-Meier analysis: red and blue lines, respectively, represent patients with
(n ¼ 14) and without (n ¼ 48) cardiac arrest (CA) before enrollment. Patients
with CA before enrollment were more likely to experience CA during follow-up
(p < 0.0000001).
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1305Our data on BrS (17) showed that 15% of patients
experience a ﬁrst CA between birth and 44 years of age,
corresponding to an annual event rate of 0.25%. In this
study, we showed that by 40 years of age, as many as
40% of our SQTS patients experienced a ﬁrst CA, with
an annual event rate of 0.9%. It appears, therefore, that
SQTS is more malignant than BrS, as also supported by
the high rate of life-threatening arrhythmias in the ﬁrst
year of life.
Sex differences. Similar to BrS, SQTS is an autosomal
dominant disease, and it should be equally prevalent in
male and female patients. However, when we establish the
diagnosis on the basis of clinical parameters, excluding the
contribution of genetic testing, the predominance of male
patients is overwhelming (91%), suggesting that SQTS has,
like BrS, a sex-dependent penetrance. However, the percent
of patients who had life-threatening arrhythmias develop is
not signiﬁcantly different in male patients compared with
female patients (30% vs. 17%, respectively; p ¼ 0.49), sug-
gesting that, in the clinics, we establish the diagnosis in
more male patients than female patients, but we should not
consider affected female patients at lower risk of CA.
Familial and sporadic forms. In this study, we report novel
data on the familial penetrance of SQTS. Familial clustering
of the short QT phenotype was present in approximately
half of SQTS probands, whereas the remaining were likely
sporadic. The percent of familial disease is higher than that
reported in BrS (28%) (18). In the familial cases, half of the
ﬁrst-degree relatives screened were clinically affected,
consistent with the known autosomal dominant pattern of
inheritance.In line with the recent consensus document on genetic
screening for channelopathies and cardiomyopathies (4),
we conﬁrmed that none of the genes related to SQTS
identiﬁes a disease-causing mutation in >5% of clinically
affected probands. Interestingly, all the mutations found in
our cohort showed a complete penetrance in carriers.
Although the relatively small number of subjects limits our
interpretation, this observation contrasts with that reported
for SCN5A mutations in BrS (<50%) (17).
Mutation carriers exhibited a signiﬁcantly shorter QTc
interval (p ¼ 0.002) compared with noncarriers, but this
ﬁnding did not correlate with a different outcome, sup-
porting the view that, at variance with long QT syndrome,
the more severe electrocardiographic phenotype is not a
prognostic indicator in SQTS (see the following) text.
Risk stratiﬁcation. To date, there are no data supporting
the efﬁcacy of pharmacological treatments to reduce the
occurrence of life-threatening arrhythmias in SQTS (19),
and implanting an ICD is the only treatment to prevent
sudden death. It is therefore important to identify clinical
markers to predict the risk of CA. Unfortunately, neither
the presence of a very short QT interval nor the history
of syncope alone identiﬁes patients at higher risk of CA.
Interestingly, analogous with what is seen in BrS (20),
inducibility of VT/VF at PES is not an independent
predictor of risk in SQTS.
In our population, the only predictor of malignant
arrhythmias at follow-up is having experienced a ﬁrst CA:
these data strongly support ICD implantation in CA sur-
vivors, given that as many as two thirds of them had a
recurrence at follow-up.
Considering the lack of individual predictors of risk in
the asymptomatic population, we investigated whether the
multiparametric risk score proposed by Gollob et al. (6,7)
could identify patients at risk of life-threatening events
in our study group. Unfortunately, this hypothesis was not
conﬁrmed. When we applied the modiﬁed Gollob score
to our study group, 5 of 8 patients who experienced CA
had a score of 3, which corresponds to a predicted
low probability of arrhythmic events. Overall, we urge
caution regarding the use of this scoring system for risk
stratiﬁcation.
Triggers for cardiac events. In our cohort, we observed
that the circumstances in which CA occurred in patients
who experienced multiple life-threatening events were
reproducible in almost 80% of cases. The majority (83%) of
CAs occurred under resting conditions or during sleep,
whereas events related to effort or intense emotions were
observed in a minority of patients (17%). In this respect,
the arrhythmic triggers in SQTS appear more similar to
BrS than to other channelopathies such as long QT syn-
drome or catecholaminergic polymorphic VT, in which
arrhythmias are precipitated by adrenergic triggers.
Electrophysiological characteristics of arrhythmias in
SQTS. The presence of a short action potential duration,
as well as an abbreviated repolarization, suggests that the
Figure 5 Onset of VF in Short QT Syndrome
(A) Baseline QTc interval reported along with the coupling interval (CI) of the ventricular ectopic beat (VEB) initiating ventricular ﬁbrillation (VF) (column 1). Tracings of VEBs
(column 2) with the same CI as the initiating beat of VF (column 3) are shown. VEBs occurred immediately before VF onset in Patients #1, #3, and #4. VF was initiated by VEBs
with a short CI in Patients #1 to #3. (B) Patient #2 had multiple polymorphic nonsustained ventricular tachycardia episodes (ﬁrst 3 rows) as a prelude to VF (fourth row) during
an arrhythmic storm. Episodes are initiated by the same VEB (CI ¼ 250 ms). ICD ¼ implantable cardioverter-deﬁbrillator.
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1306R-on-T phenomenon may precipitate arrhythmogenesis in
SQTS. Unexpectedly, however, we documented that either
long- or short-coupled extrasystolic beats initiated VF in
our patients. Although the mechanism for VF/VT initi-
ated by long-coupled extrasystoles remains speculative, the
arrhythmogenic mechanism for VF/VT elicited by short-coupled beats may be explained by the results of the
in silico characterization of a KCNJ2 gain-of-function
mutation identiﬁed in one of our SQTS patients with
an extremely short QT interval (14). In that study, we
showed that the Purkinje network, because of its markedly
abbreviated refractory period, creates a functional accessory
Figure 6 Multiple Episodes of VF in 2 Patients
(A) Patient #1. Telemetry tracings (rows 1 to 3) from an arrhythmic storm and an ICD tracing (row 4) of an unrelated episode of VF. Arrhythmias (in the absence of amiodarone)
were initiated by the same short-coupled (CI¼ 230 ms) ventricular extrasystolic beats. (B) Patient #2. Two successive episodes of VF within the same arrhythmic storm initiated
by the same long-coupled ventricular extrasystolic beats (CI ¼ 350 ms). Abbreviations as in Figure 5.
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1307pathway through which short-coupled extrasystoles could
initiate reentry.
Interestingly, the mode of onset of VF observed in SQTS
is similar to that seen in idiopathic VF, supporting the
idea that some patients with idiopathic VF may have a
forme fruste of SQTS (21).
Study limitations. This study provides registry data and,
although the authors clinically evaluated all patients, there
has been no uniform protocol for clinical assessment and
treatment. Moreover, ascertainment bias, which typically
selects highly affected patients during the early character-
ization of disorders, is likely to be present. Furthermore,despite careful investigation into the nature of syncope, we
cannot fully exclude that vagal episodes might have been
present in some patients.Conclusions
Despite the limited number of patients with SQTS, the
understanding of the clinical features of the disease is
steadily progressing. The present study reports the largest
series of SQTS patients prospectively followed and provides
novel observations with a practical impact on clinical man-
agement. The evidence that there is an age dependency
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occurrence of CA in the ﬁrst year of life and a second peak
between 20 and 40 years of age, is relevant. In fact, it points
to the value of extending clinical evaluation to family
members of SQTS probands and highlights the importance
of electrocardiographic evaluation of newborns in SQTS
families. Our data also show the presence of a strong male
predominance in the manifestation of an abbreviated repo-
larization. However, we highlight the view that women
should not be regarded as low-risk patients because female
patients presenting with a short QT interval have a risk of
experiencing CA that is similar to that of male patients.
The challenge for the management of patients with
SQTS remains the paucity of risk stratiﬁcation indexes. To
date, no risk indicator has been identiﬁed. Our data show
that the prognostic score proposed by Gollob et al. (6,7) is
not able to identify patients who experienced CA in our
population. In this study, we showed that having survived a
ﬁrst occurrence of CA is a strong predictor of recurrences.
This information is important because it supports the need
to consider implanting an ICD for secondary prevention of
CA even in young SQTS patients.
The most urgent challenge in SQTS is to identify indi-
cators of a propensity toward CA among asymptomatic
patients. Perhaps as larger series of patients with longer
follow-up become available, it will be possible to provide
evidence-based data for the management of asymptomatic
SQTS subjects and tailor the use of the ICD to the higher
risk subgroup.
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